Discussion
Halofantrine is an antimalarial drug which is effective against all species of Plasmodium, very well tolerated, and has a simple dosage regimen. It belongs to a class of compounds, the phenanthrene-methanols, which do not share chemical structure with any other antimalarials, and is therefore particularly effective in the treatment of drug-resistant falciparum malaria3). Although resistance of vivax malaria to chloroquine has occurred only occasionally so far, it is now firmly established in the island of New Guinea (Indonesia and Papua New Guinea)14,15). Therefore, it has to be taken into consideration that Halfan(R) can be the drug of first choice even for patients who have contracted vivax malaria. In P. vivax malaria, the mean parasite clearance time was 62 hours and the mean fever clearnace time was 42 hours after treatment by Halfan(R). The patient reported here was apparently thought to have been successfully treated; parasites were cleared by 69 hours and the fever fell to normal in 9 hours, without any signs or symptoms of the side effects of the drug. However, ECG revealed by dysrythmiasis with prolongation of the QT intervals following treatment with Halfan(R). These ECG changes were reported to be brought about by the increased myocardial concentrations of halofantrine or its biologically active metabolite9), but not associated with desbutylhalofantrine (one of the metabolites of halofantrine)12). And the fact that these effects are similar to those of quinine16) suggests caution in treating patients previously administered quinine (or vice versa)12). In accordance with advice from the pharmaceutical company, WHO announced a drug alert for halofantrine13) to reduce the cardiac effects of the drug to a minimum: a) It is contraindicated in patients with a family history of congenital QT prolongation. b) It is not recommended for usage in combination with drugs or clinical conditions known to prolong the QT interval or in patients who may suffer from thiamine deficiency. c) It should not be administered to patients with severe electrolyte imbalance. d) The treatment should not exceed the recommended total dosage of 24 mg/ kg given as 8 mg/kg 3 times at 6-hour intervals. e) It should be administered on an empty stomach (i. e. not given in association with food). f) It should only be used as emergency self-medication for presumptive therapy in those patients known to have normal QT intervals. Abiding by the conditions mentioned above, we experienced the first case of vivax malaria in a Japanese patient who showed abnormal ECG findings following treatment with halofantrine. Further careful studies on individual Japanese patients to confirm its efficacy or tolerance should be required, before halofantrine is generally used in Japan.
